2411: Poolbeg Pharma: What US Payers Really Said
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
2411: Poolbeg Pharma: What US Payers Really Said
-
Narrated by:
-
By:
Watch on YouTube
Independent US payer research commissioned by Poolbeg Pharma shows strong commercial backing for POLB 001 — a first-in-class preventative for cancer immunotherapy-induced CRS. Chris from Acumentis Global on what payers said, and what it means for the commercial opportunity ahead.
adbl_web_anon_alc_button_suppression_t1
No reviews yet